{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:53:10Z","timestamp":1777103590386,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T23:13:47Z","timestamp":1754694827000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0117-6363","authenticated-orcid":false,"given":"Bethany Rachel","family":"O'Neill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4356-2615","authenticated-orcid":false,"given":"Andrew","family":"Ginn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menuk","family":"Jayawardena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.08.002_bib0001","series-title":"Australian Passive Antimicrobial Resistance Surveillance \u2013 third-generation cephalosporin resistance in Escherichia coli and Klebsiella pneumoniae: prevalence of extended-spectrum \u03b2-lactamase (ESBL) phenotype","year":"2022"},{"key":"10.1016\/j.jgar.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/AAC.02052-13","article-title":"Australasian Society for Infectious Diseases Clinical Research Network. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries","volume":"58","author":"Rogers","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/2277-9175.166643","article-title":"Detection of ESBL- and AmpC-producing E. coli isolates from urinary tract infections","volume":"4","author":"Shayan","year":"2015","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.jgar.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.18773\/austprescr.2020.008","article-title":"Oral or intravenous antibiotics?","volume":"43","author":"McCarthy","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jgar.2025.08.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.11.008","article-title":"Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model","volume":"55","author":"Zykov","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2025.08.002_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/46.suppl_1.9","article-title":"Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases","volume":"46","author":"Sougakoff","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000237814","article-title":"Urinary excretion of mecillinam by volunteers receiving film-coated tablets of pivmecillinam hydrochloride","volume":"25","author":"Anderson","year":"1979","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jgar.2025.08.002_bib0008","doi-asserted-by":"crossref","first-page":"dlac125","DOI":"10.1093\/jacamr\/dlac125","article-title":"A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems","volume":"4","author":"Gandra","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.08.002_bib0009","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","article-title":"Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria","volume":"82","author":"Zhanel","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkm063","article-title":"Activity of faropenem against cephalosporin-resistant Enterobacteriaceae","volume":"59","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2025.08.002_bib0011","first-page":"82","article-title":"Pharmacokinetics and safety of oral carbapenem antibiotic tebipenem pivoxil tablets in healthy male volunteers","volume":"57","author":"Nakashima","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.pathol.2020.10.016","article-title":"Mecillinam susceptibility in Victorian third generation cephalosporin-nonsusceptible Escherichia coli urinary isolates","volume":"53","author":"Olenski","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.jgar.2025.08.002_bib0013","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jpc.14883","article-title":"Potential of fosfomycin in treating multidrug-resistant infections in children","volume":"56","author":"Williams","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.jgar.2025.08.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02083-18","article-title":"Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study","volume":"63","author":"Overcash","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.08.002_bib0016","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jgar.2025.08.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007218","article-title":"Host adaptation and convergent evolution increases antibiotic resistance without loss of virulence in a major human pathogen","volume":"15","author":"Fajardo-Lubi\u00e1n","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jgar.2025.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/jac\/dkac045","article-title":"Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model","volume":"77","author":"Abbott","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0021","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jiph.2019.05.012","article-title":"Oral treatment options for patients with urinary tract infections caused by extended spectrum \u03b2eta-lactamase (ESBL) producing Enterobacteriaceae","volume":"12","author":"Raja","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.13387","article-title":"Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum \u03b2eta-lactamase (ESBL) producing Enterobacteriaceae","volume":"73","author":"Raja","year":"2019","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jgar.2025.08.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/mdr.2019.0423","article-title":"Activity of omadacycline and other tetracyclines against contemporary Gram-negative pathogens from New York City hospitals","volume":"27","author":"Iregui","year":"2021","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2025.08.002_bib0025","article-title":"In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli","volume":"63","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02618-18","article-title":"Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of enterobacteriaceae isolates, including a challenge set of organisms","volume":"63","author":"Arends","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0027","doi-asserted-by":"crossref","first-page":"dlac105","DOI":"10.1093\/jacamr\/dlac105","article-title":"Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections","volume":"4","author":"Ranasinghe","year":"2022","journal-title":"JAC-Antimicrobial Resistance"},{"key":"10.1016\/j.jgar.2025.08.002_bib0028","series-title":"Penicillins and Cephalosporins. Chemotherapy","article-title":"The Disposition of Mecillinam and Pivmecillinam in Man","volume":"5","author":"Andrews","year":"1976"},{"key":"10.1016\/j.jgar.2025.08.002_bib0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2004.00737.x","article-title":"Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole","volume":"10","author":"Kerrn MB","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.08.002_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11908-024-00831-1","article-title":"Tebipenem and sulopenem: dynamic duo or double trouble?","volume":"26","author":"Mangum","year":"2024","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jgar.2025.08.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00618-19","article-title":"Safety, pharmacokinetics, and food effect of tebipenem pivoxil hydrobromide after single and multiple ascending oral doses in healthy adult subjects","volume":"63","author":"Eckburg","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0032","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/jac\/dkx081","article-title":"Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial","volume":"72","author":"Gurumurthy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0033","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpba.2009.12.010","article-title":"High-throughput determination of faropenem in human plasma and urine by on-line solid-phase extraction coupled to high-performance liquid chromatography with UV detection and its application to the pharmacokinetic study","volume":"52","author":"Xie","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jgar.2025.08.002_bib0034","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antibiotics6040024","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.08.002_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40261-022-01119-9","article-title":"Omadacycline oral dosing and pharmacokinetics in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection","volume":"42","author":"Leviton","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jgar.2025.08.002_bib0036","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcph.1041","article-title":"Delafloxacin pharmacokinetics in subjects with varying degrees of renal function","volume":"58","author":"Hoover","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2025.08.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02349-16","article-title":"Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States","volume":"61","author":"Satlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0039","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/AAC.04819-14","article-title":"Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli","volume":"59","author":"Thulin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.002_bib0040","series-title":"Manual of Clinical Microbiology","article-title":"Antibacterial Agents. Chapter 68","author":"Lewis","year":"2015"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:16:50Z","timestamp":1777101410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S2213716525001857"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.08.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}